number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion cardura usage with diabetes ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription onlyRoutes.

quinazolin-2-yl) piperazin-1-yl]- cardura usage with diabetes deca-6,8,10-trien-4-yl) methanoneIdentifiersCAS number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription onlyRoutes oralDoxazosin mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura® and Carduran® , is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA cardura usage with diabetes a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha-1 cardura usage with diabetes receptor blocker which inhibits the binding of norepinephrine cardura usage with diabetes alpha receptors in the autonomic nervous system. The cardura usage with diabetes effect cardura usage with diabetes this blockage is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular.

to alpha receptors in the autonomic nervous system. cardura usage with diabetes primary effect of this blockage is relaxed vascular.